Reversal of subclinical adrenal insufficiency through antituberculosis treatment in TB patients: a longitudinal follow up.
OBJECTIVE
Subclinical adrenal insufficiency has been shown to occur in patients with tuberculosis. Whether this insufficiency can be reversed with therapy and on long-term follow up, is not known. We studied the effect of antituberculosis treatment (ATT) with respect to reversal of the adrenal insufficiency, as assessed by response to standard dose adrenocorticotropin (ACTH) stimulation test in TB patients.


METHODS
One hundred and five HIV-negative tuberculosis patients were studied. Of these, 72 patients had pulmonary and 33 had extrapulmonary forms of the disease. Baseline (pre-treatment) standard-dose ACTH stimulation test was done on all the subjects, following which, they were put on standard antituberculosis therapy, depending on the type of disease and were followed up for a period of 30 months. ACTH stimulation tests were performed at follow up, every 6 months.


RESULTS
Baseline (pre-treatment) standard-dose ACTH stimulation test revealed an impaired response in 52 of 105 patients (49.5%). At 6 months, the percentage of responders had increased to 71 per cent with a gradual increasing trend noted thereafter. At 24 months, 31 of the 32 patients (97%) who were followed up demonstrated a normal response to ACTH stimulation. The percentage of responders was comparable in both pulmonary [21 of 22 patients (95%)] and extrapulmonary TB [10 of 10 patients (100%)] groups at follow up.


CONCLUSIONS
Our study shows that nearly half of patients with active tuberculosis had a subclinical adrenal insufficiency indicated by an impaired response to ACTH stimulation test. This insufficiency reverse with therapy in most patients on long-term follow up.
Sharma
S K
SK
Department of Medicine, All India Institute of Medical Sciences, New Delhi 110-029, India. sksharma@aiims.ac.in
Tandan
S M
SM
Saha
P K
PK
Gupta
N
N
Kochupillai
N
N
Misra
N K
NK
D000309:Adrenal Insufficiency / Q000188:drug therapy*; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000328:Adult; D000995:Antitubercular Agents / Q000494:pharmacology*; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism; D008297:Male; D013997:Time Factors; D014376:Tuberculosis / Q000150:complications* / Q000188:drug therapy*; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy
D000995:Antitubercular Agents; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone